MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$56,698K
Net Income
-$53,387K
Net Profit Margin
-94.16%
EPS
-$0.32
Unit: Thousand (K) dollars
Revenue Breakdown
Sanofi
Supply Sales
Serum
Others
Revenue Breakdown
us-us-US
rest of the world-rest of the wo...
europe-europe-Europe
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
56,698
139,514
147,139
70,445
Cost of sales
14,246
30,695
22,104
21,496
Research and development
70,693
95,472
75,876
98,274
Selling, general, and administrative
26,665
28,777
62,514*
31,655
Impairment of assets held for sale
-
-
-27,585*
97,038
Total expenses
111,604
154,944
132,909
248,463
Income (loss) from operations
-54,906
-15,430
14,230
-178,018
Interest expense
5,689
4,901
5,824
5,482
Gain on debt extinguishment
-
-
0*
-28,714
Gain on disposition of novavax cz assets
-
-
0*
-
Other income, net
8,919
11,825
9,497
9,178
Income (loss) before income tax expense
-51,676
-8,506
17,903
-203,036
Income tax expense
1,711
985
376
-657
Net income (loss)
-53,387
-9,491
17,527
-202,379
Basic EPS
-0.32
-0.06
0.108
-1.25
Diluted EPS
-0.32
-0.06
0.1
-1.25
Basic Average Shares
164,574,000
163,276,000
162,543,000
162,353,000
Diluted Average Shares
164,574,000
163,276,000
175,219,000
162,353,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Net income (loss)
-$53,387K
(-150.12%↓ Y/Y)
Sanofi
$35,768K
Serum
$1,823K
Takeda
$215K
Other Partners
$38K
Supply Sales
$18,854K
Income (loss) before
income tax expense
-$51,676K
(-148.09%↓ Y/Y)
Income tax expense
$1,711K
(80.87%↑ Y/Y)
Other income, net
$8,919K
(-25.06%↓ Y/Y)
Licensing Royalties And
Other
$37,844K
Product
$18,854K
Income (loss) from
operations
-$54,906K
(-154.32%↓ Y/Y)
Total revenue
$56,698K
(-76.30%↓ Y/Y)
Interest expense
$5,689K
(3.10%↑ Y/Y)
Total expenses
$111,604K
(-19.23%↓ Y/Y)
Research and development
$70,693K
(-10.78%↓ Y/Y)
Selling, general, and
administrative
$26,665K
(-38.86%↓ Y/Y)
Cost of sales
$14,246K
(-7.04%↓ Y/Y)
Buy us a coffee
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)